Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

28 Feb 2023 08:00 CET

Bomi Framroze Holding AS, a close associate of primary insider and Chief
Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27
February 2023 purchased 200,000 shares in HBC at a price of NOK 2.69 per share.

Please see the attached notification form for further information.

Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

This information is subject to the disclosure requirements in the Market Abuse
Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading
Act section 5-12.

More information:
Access the news on Oslo Bors NewsWeb site

583781_PDMR notification form - Bomi Framroze Holding AS.pdf